SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced results of preclinical studies, which suggest that pimavanserin, ACADIA’s proprietary product candidate currently in Phase III development for Parkinson’s disease psychosis, also may have therapeutic benefits in the treatment of Alzheimer’s disease psychosis (ADP). Results of these studies were published in the scientific journal, Behavioural Pharmacology (Price et al., “Pimavanserin, a 5-HT2A Receptor Inverse Agonist, Reverses Psychosis-like Behaviors in a Rodent Model of Alzheimer’s Disease,” July 2012 e-pub).
